
Academic Journal
Q2Breast Cancer: Targets and Therapy
About Breast Cancer: Targets and Therapy
Breast Cancer: Targets and Therapy is a scholarly journal published by Dove Medical Press Ltd. SCImago 2025 lists it in Q2, with an SJR of 0.992 and H-index of 51.
Coverage: 2010-2026. Research categories: Oncology (Q2).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-04-27. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Breast Cancer Treatment Studies; HER2/EGFR in Cancer Research; Advanced Breast Cancer Therapies; Breast Lesions and Carcinomas; Cancer Treatment and Pharmacology; Global Cancer Incidence and Screening.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
D-Dimer Dynamics as a Prognostic and Monitoring Biomarker in Triple-Negative and Metastatic Breast Cancer: A Narrative Review
Emmanuel Ifeanyi Obeagu
2026-10 · DOI: 10.2147/bctt.s637558Investigation of the Residual Tumor Burden and Prognosis of Breast Cancer
Angela de Salles Rezende, Teresa Cristina Ferreira Gutman, Karin Soares Cunha, Fabiana Resende Rodrigues et al.
2026-09 · DOI: 10.2147/bctt.s626207Pathological Complete Response and Safety of Neoadjuvant Pembrolizumab-Based Chemoimmunotherapy in Triple-Negative and Hormone Receptor-Low Breast Cancer: A Real-World Cohort Study
Baha Sharaf, Tamer Albatsh, Suhaib Khater, Rawaa Alrabie et al.
2026-09 · DOI: 10.2147/bctt.s636314Cytoplasmic Basigin Localization is Associated with EMT, Tumor Budding, and Adverse Prognosis in Breast Cancer
Xiaoyan Xu, Yaozhong Zhang, Huijuan Fang, Xianwei Xu et al.
2026-09 · DOI: 10.2147/bctt.s631016Prognostic Significance of the Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio (TG/HDL-C) in Breast Cancer Patients: A Real-World Retrospective Study
Shuang Zhang, Jing Zhao, Yuzhe Zhao, Zheng Zhi et al.
2026-09 · DOI: 10.2147/bctt.s619932BET Protein Degrader ZBC260 Induces Tumor Vascular Reprogramming Through Endothelial Cell Remodeling
Deeksha Sharma, Cody G Hager, Max S Wicha, Monika L Burness et al.
2026-09 · DOI: 10.2147/bctt.s626513Nanomedicine-Based Strategies Targeting Macrophage Polarization in Breast Cancer Bone Metastasis: An Updated Review
Hong Wang, Rui Tian, Jian Li, Wenjing Liu et al.
2026-09 · DOI: 10.2147/bctt.s588449Development of a Consensus-Based Risk Stratification Algorithm for HR+/HER2− Early Breast Cancer to Guide Adjuvant CDK4/6i Therapy: Outcomes from a Multidisciplinary Workshop in India
Krishna Mohan Mallavarapu, Rakesh Reddy B, Somashekhar SP, Pankaj Goyal et al.
2026-09 · DOI: 10.2147/bctt.s620643AOH1996, an Inhibitor of PCNA, Sensitises Breast Cancer Cells to Cytotoxic Chemotherapy
Radhika Aiyappa-Maudsley, Thomas A Hughes
2026-09 · DOI: 10.2147/bctt.s636967Evaluation of Diagnostic Accuracy of Combined Ultrasound Elastography and Magnetic Resonance Imaging in Breast Cancer
Penghua Zhang , Yang Gu
2026-09 · DOI: 10.2147/bctt.s635995RNA-Binding Protein CSTF2 Drives Immune Evasion and Malignant Progression in Breast Cancer by Degrading THSD1 mRNA
TangXiaoMan Wang, Lei Yan, JiaLi Jiang, Jing He et al.
2026-09 · DOI: 10.2147/bctt.s620942Pharmacological Myristoylation Inhibition by Zelenirstat Disrupts Growth Signalling, Energy Metabolism, and Migration in Triple-Negative Breast Cancer Cells
Rony Pain, Erwan Beauchamp, Shawn Duckett, Morris A Kostiuk et al.
2026-09 · DOI: 10.2147/bctt.s619042MST1 and CPNE1 Emerge as Candidate Targets in Breast Cancer: Integration of Mendelian Randomization, Multi-omics Validation, and Functional Interrogation
Meng Jiang, Qilong Wang, Hong Xu
2026-08 · DOI: 10.2147/bctt.s611734MCV–Neutropenia Risk Score and Overall Survival in HR+/HER2− Advanced Breast Cancer: A Multicenter Retrospective Landmark Analysis
Fatih Atalah, Aydın Acarbay, Akgün Karakök, İsmail Nazlı et al.
2026-08 · DOI: 10.2147/bctt.s624272Association of Pretreatment ANR and IronMLR With Pathological Response Following Neoadjuvant Chemotherapy in Breast Cancer
Emre Özge, Rıza Umar Gürsu, Bünyamin Güney, Özgür Han et al.
2026-08 · DOI: 10.2147/bctt.s623894Bilateral Primary Breast Cancer: Current Evidence and Future Perspectives
Huixi Zhong, Di Lu, Yaling Zeng, Xihui Tu et al.
2026-08 · DOI: 10.2147/bctt.s615577Exosomal miR-21 Derived from Paclitaxel-Resistant Breast Cancer Cells Promotes Chemoresistance in Breast Cancer via p53/PI3K/AKT/mTOR Signaling
Yanyan Wang, Qing Cai
2026-07 · DOI: 10.2147/bctt.s615413CYP4B1 Expression in Breast Cancer: An Immunohistochemical Study with Complementary in silico Analyses
Yousef M Al-saraireh, Fatemah OFO Alshammari, Heba A Hassan, Jaber H Jaradat et al.
2026-07 · DOI: 10.2147/bctt.s612743Application of Shear Wave Elastography Combined with Tumor Markers in the Differential Diagnosis of Benign and Malignant Breast Masses
Jing Liu, Yuke Zhang, Qiang Zhou
2026-07 · DOI: 10.2147/bctt.s614367Lipid Metabolic Reprogramming in Breast Cancer: Mechanisms and Emerging Therapeutic Strategies
Xuliren Wang, Yuanyuan Zhao, Siqi Peng, Xuelong Wang et al.
2026-07 · DOI: 10.2147/bctt.s591634Reviews
Community Reviews
Version History
October 4, 2026 at 8:59 pm
October 2, 2026